• 1
    Young NS, Issaragrisil S, Ch'en CW, Takaku F. Aplastic anaemia in the Orient. Br J Haematol 1986; 62: 16.
  • 2
    Vincent PC. Drug induced aplastic anemia and agranulocytosis. Drugs 1986; 31: 5263.
  • 3
    Bessler M, Hillmen P. Somatic mutation and clonal selection in the pathogenesis and in the control of paroxysmal nocturnal hemoglobinuria. Semin Hematol 1998; 35: 149167.
  • 4
    Luzzatto L. Paroxysmal murine hemoglobinuria (? ): a model for human PNH. Blood 1999; 94: 29412944.
  • 5
    Hillmen P, Richards SJ. Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2000; 108: 470479.
  • 6
    Strubing P. Paroxysmal hemoglobinuria. Dtsch Med Wochenschr 1882; 8: 13.
  • 7
    Ham TH, Dingle JH. Studies on the destruction of red blood cells. II. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria. Certain immunological aspects of the hemolytic mechanism with special reference to serum complement. J Clin Invest 1939; 18: 657672.
  • 8
    Beck WS, Valentine WN. Biochemical studies on leucocytes. II. Phosphate activity in chronic lymphatic leukemia, acute leukemia and miscellaneous hematologic conditions. J Lab Clin Med 1951; 38: 245253.
  • 9
    Lewis SM, Dacie JV. Neutrophil (leucocyte) alkaline phosphatase in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1965; 11: 549556.
  • 10
    Dacie JV. Paroxysmal nocturnal haemoglobinuria. Proc R Soc Med 1963; 56: 587596.
  • 11
    Oni SB, Osunkoya BO, Luzzatto L. Paroxysmal nocturnal hemoglobinuria: evidence for monoclonal origin of abnormal red cells. Blood 1970; 36: 145152.
  • 12
    Nicholson-Weller A, March JP, Rosenfeld JP, Austen KF. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay acceleration factor. Proc Natl Acad Sci USA 1983; 80: 50665070.
  • 13
    Holguin MH, Frederick LR, Bernshaw NJ, Wilcox LA, Parker CJ. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1989; 84: 717.
  • 14
    Armstrong C, Schubert J, Ueda E, Knez JJ, Gelperin D, Hirose S, Silber R, Hollan S, Schmidt RE, Medof ME. Affected paroxysmal nocturnal hemoglobinuria T lymphocytes harbour a common defect in assembly of N-acetyl-D-glucosamine inositol phospholipid corresponding to that in class A Thy-1-murine lymphoma mutants. J Biol Chem 1992; 267: 2534725351.
  • 15
    Hillmen P, Bessler M, Mason PJ, Watkins WM, Luzzatto L. Specific defect in N-acetylglucosamine incorporation in the GPI-anchor synthetic pathway in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 1993; 90: 52725276.
  • 16
    Takahashi M, Takeda J, Hirose S, Hyman R, Inoue N, Miyata T, Ueda E, Kitani T, Medof ME, Kinoshita T. Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 1993; 177: 517521.
  • 17
    Miyata T, Takeda J, Iida Y, Yamada N, Inoue N, Takahashi M, Maeda K, Kitani T, Kinoshita T. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993; 259: 13181320.
  • 18
    Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, Takahashi M, Kitani T, Kinoshita T. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993; 73: 703711.
  • 19
    Bessler M, Mason PJ, Hillmen P, Miyata T, Yamada N, Takeda N, Luzzatto L, Kinoshita T. Paroxysmal nocturnal hemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO-J 1994; 13: 110117.
  • 20
    Nafa K, Bessler M, Castro-Malaspina H, Jhanwar S, Luzzatto L. The spectrum of somatic mutations in the PIG-A gene in paroxysmal nocturnal hemoglobinuria includes large deletions and small duplications. Blood Cells Mol Dis 1998; 24: 370384.
  • 21
    Ware RE, Nishimura J, Moody NA, Smith C, Rosse WF, Howard TA. The PIG-A mutation and absence of glycosylphosphatidylinositol-linked proteins do not confer resistance to apoptosis in paroxysmal nocturnal hemoglobinuria. Blood 1998; 92: 25412550.
  • 22
    Kinoshita T, Medof ME, Silber R, Nussenzweig V. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 1985; 162: 7592.
  • 23
    Nicholson-Weller A, Spicer DB, Austen KF. Deficiency of the complement regulatory protein, “decay-accelerating factor,” on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria. N Engl J Med 1985; 312: 10911097.
  • 24
    Kanamaru A, Okuda K, Ueda E, Kitani T, Kinoshita T, Nagai K. Different distribution of decay accelerating factor on hematopoietic progenitors from normal individuals and patients with paroxysmal nocturnal hemoglobinuria. Blood 1988; 72: 507511.
  • 25
    van der Schoot CE, Huizinga TW, van't Veer-Korthof ET, Wijmans R, Pinkster J, von dem Borne AE. Deficiency of glycosyl-phosphatidylinositol-linked membrane glycoproteins of leukocytes in paroxysmal nocturnal hemoglobinuria, description of a new diagnostic cytofluorometric assay. Blood 1990; 76: 18531859.
  • 26
    Schubert J, Alvarado M, Uciechowski P, Zielinska-Skowronek M, Freund M, Vogt H, Schmidt RE. Diagnosis of paroxysmal nocturnal haemoglobinuria using immunophenotyping of peripheral blood cells. Br J Haematol 1991; 79: 487492.
  • 27
    Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 12531258.
  • 28
    Socie G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, Heudier P, Rochant H, Cahn JY, Gluckman E. Paroxysmal nocturnal haemoglobinuria: long term follow-up and prognostic factors. French society for haematology. Lancet 1996; 348: 573577.
  • 29
    Hillmen P, Richards SJ, Baker AJ, Rawstron AC, Crawford DH, Layton DM. Congenital paroxysmal nocturnal hemoglobinuria. Blood 1998; 92 (supplement 1): 154a.
  • 30
    Valla D, Dhumeaux D, Babany G, Hillon P, Rueff B, Rochant H, Benhamou JP. Hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria. A spectrum from asymptomatic occlusion of hepatic venules to fatal Budd-Chiari syndrome. Gasteroenterology 1987; 93: 569575.
  • 31
    Ham T. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: study of the mechanism of hemolysis in relation to the acid-base equilibrium. N Engl J Med 1937; 915: 915917.
  • 32
    Hartmann RC, Jenkins DE. The “sugar-water” test for paroxysmal nocturnal hemoglobinuria. N Engl J Med 1966; 275: 155157.
  • 33
    Rosse WF. Variations in the red cells in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1973; 24: 327342.
  • 34
    Hall SE, Rosse WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood 1996; 87: 53325340.
  • 35
    Navenot JM, Bernard D, Harousseau JL, Muller JY, Blanchard D. Expression of glycosyl-phosphatidylinositol-linked glycoproteins in blood cells from paroxysmal nocturnal hemoglobinuria patients. A flow cytometry study using CD55, CD58 and CD59 monoclonal antibodies. Leuk Lymphoma 1996; 21: 143151.
  • 36
    Alfinito F, Del Vecchio L, Rocco S, Boccuni P, Musto P, Rotoli B. Blood cell flow cytometry in paroxysmal nocturnal hemoglobinuria: a tool for measuring the extent of the PNH clone. Leukemia 1996; 10: 13261330.
  • 37
    Rosse WF, Dacie JV. The role of complement in the sensitivity of the paroxysmal nocturnal hemoglobinuria red cell to immune lysis. Bibl Haematol 1965; 23: 1118.
  • 38
    Nilsson B, Hagstrom U, Englund A, Safwenburg J. A simplified assay for the specific diagnosis of paroxysmal nocturnal hemoglobinuria: detection of DAF(CD55)- and HRF20 (CD59)-erythrocytes by microtyping cards. Vox Sang 1993; 64: 4346.
  • 39
    Mandy FF, Bergeron M, Minkus T. Evolution of leukocyte immunophenotyping as influenced by the HIV/AIDS pandemic: a short history of the development of gating strategies for CD4+ T-cell enumeration. Cytometry 1997; 30: 157165.
  • 40
    Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR. Single platform flow cytometric absolute CD34+ cell counts based on ISHAGE guidelines. International society of hematotherapy and graft engineering. Cytometry 1998; 34: 6170.
  • 41
    Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1997; 90: 28632892.
  • 42
    Reid ME, Mallinson G, Sim RB, Poole J, Pausch V, Merry AH, Liew YW, Tanner MJ. Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating factor deficiency). Blood 1991; 78: 32913297.
  • 43
    Yamashina M, Ueda E, Kinoshita T, Takami T, Ojima A, Ono H, Tanaka H, Kondo N, Orii T, Okada N, Okada H, Inoue K, Kitani T. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1990; 323: 11841189.
  • 44
    Navenot JM, Muller JY, Blanchard D. Investigation of the survival of paroxysmal nocturnal hemoglobinuria red cells through the immunophenotyping of reticulocytes. Transfusion 1998; 38: 337342.
  • 45
    Ware RE, Rosse WF, Hall SE. Immunophenotypic analysis of reticulocytes in paroxysmal nocturnal hemoglobinuria. Blood 1995; 86: 15861589.
  • 46
    Iwamoto N, Kawaguchi T, Nagakura S, Hidaka M, Horikawa K, Kagimoto T, Takatsuki K, Nakakuma H. Markedly high population of affected reticulocytes negative for decay-accelerating factor and CD59 in paroxysmal nocturnal hemoglobinuria. Blood 1995; 85: 22282232.
  • 47
    Stadler BM. Antibody production without animals. Dev Biol Stand 1999; 101: 4548.
  • 48
    Kwong YL, Lee CP, Chan TK, Chan LC. Flow cytometric measurement of glycosylphosphatidyl-inositol-linked surface proteins on blood cells of patients with paroxysmal nocturnal hemoglobinuria. Am J Clin Pathol 1994; 102: 3035.
  • 49
    Schmidt RE, Perussia B. Cluster report: CD16. In: KnappW, DörkenB, GilksWR, ReiberEP, SchmidtRE, SteinH, von dem BorneAEGKr, editors. Leucocyte typing IV white cell differentiation antigens. Oxford: Oxford University Press; 1989 p. 574578.
  • 50
    Hillmen P, Bessler M, Crawford DH, Luzzatto L. Production and characterization of lymphoblastoid cell lines with the paroxysmal nocturnal hemoglobinuria phenotype. Blood 1993; 81: 193199.
  • 51
    Richards SJ, Norfolk DR, Swirsky DM, Hillmen P. Lymphocyte subset analysis and glycosylphosphatidylinositol phenotype in patients with paroxysmal nocturnal hemoglobinuria. Blood 1998; 92: 17991806.
  • 52
    Fujioka S, Yamada T. Varying populations of CD59 negative, partly positive, and normally positive blood cells in different cell lineages in peripheral blood of paroxysmal nocturnal hemoglobinuria patients. Am J Hematol 1994; 45: 122127.
  • 53
    Nagakura S, Nakakuma H, Horikawa K, Hidaka M, Kigimoto T, Kawakita M, Tomita M, Takatsuki K. Expression of decay-accelerating factor and CD59 in lymphocyte subsets of healthy individuals and paroxysmal nocturnal hemoglobinuria patients. Am J Hematol 1993; 43: 1418.
  • 54
    Richards SJ, Morgan GJ, Hillmen P. Analysis of T cells in paroxysmal nocturnal hemoglobinuria (PNH) provides direct evidence that thymic T cell production declines with age. Blood 1999; 94: 27902799.
  • 55
    Tseng JE, Hall SE, Howard TA, Ware RE. Phenotypic and functional analysis of lymphocytes in paroxysmal nocturnal hemoglobinuria. Am J Hematol 1995; 50: 244253.
  • 56
    Nakakuma H, Nagakura S, Kawaguchi T, Iwamoto N, Hidaka M, Horikawa K, Kagimoto T, Tsuruzaki R, Takatsuki K. Persistence of affected T lymphocytes in long-term clinical remission in paroxysmal nocturnal hemoglobinuria. Blood 1994; 84: 39253928.
  • 57
    Hugul B, Socie G, Vu T, Toti F, Gluckman E, Freyssinet JM, Scrobohaci ML. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999; 93: 34513456.
  • 58
    Gralnick HR, Vail M, McKeown LP, Merryman P, Wilson O, Chu I, Kimball J. Activated platelets in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995; 91: 697702.
  • 59
    Dunn DE, Ware RE, Parker CJ, Mishoe HO, Young NS. Research directions in paroxysmal nocturnal hemoglobinuria. Immunol Today 1999; 20: 168171.
  • 60
    Maciejewski JP, Young NS, Yu M, Anderson SM, Sloand EM. Analysis of the expression of glycosylphosphatidylinositol anchored proteins on platelets from patients with paroxysmal nocturnal hemoglobinuria. Thromb Res 1996; 83: 433447.
  • 61
    Vu T, Griscelli-Bennaceur A, Gluckman E, Sigaux F, Carosella ED, Menier C, Scrobohaci ML, Socie G. Aplastic anemia and paroxysmal nocturnal haemoglobinuria: a study of the GPI-anchored proteins on human platelets. Br J Haematol 1996; 93: 586589.
  • 62
    Jin JY, Tooze JA, Marsh JC, Gordon-Smith EC. Glycosylphosphatidyl-inositol (GPI)-linked protein deficiency on the platelets of patients with aplastic anemia and paroxysmal nocturnal haemoglobinuria: two distinct patterns correlating with expression on neutrophils. Br J Haematol 1997; 96: 493496.
  • 63
    Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci USA 1999; 96: 52095214.
  • 64
    Dacie JV. Paroxysmal nocturnal hemoglobinuria. Sangre 1980; 25: 890895.
  • 65
    Rotoli B, Luzzatto L. Paroxysmal nocturnal hemoglobinuria. Semin Hematol 1989; 26: 201207.
  • 66
    Rawstron AC, Rollinson SJ, Richards SJ, Short MA, English A, Morgan GJ, Hale G, Hillmen P. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br J Haematol 1999; 107: 148153.
  • 67
    Hale G, Xia MQ, Tighe HP, Dyer MJS, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990; 35: 118127.
  • 68
    Hertenstein B, Wagner B, Bunjes D, Duncker C, Raghavachar A, Arnold R, Heimpel H, Schrezenmeier H. Emergence of CD52, phosphatidyl-inositolglycan-deficient T-lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood 1995; 86: 14871492.
  • 69
    Pawson R, Dyer MJ, Barge R, Matutes E, Thornton PD, Emmett E, Kluin-Nelemans JC, Fibbe WE, Willemze R, Catovsky D. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997; 15: 26672672.
  • 70
    Hillmen P, Richards SJ. Flow cytometry in PNH: serial analysis and the prediction of outcome. Blood 1999; 94 (supplement 1): 412a.
  • 71
    Dacie JV, Lewis SM. Paroxysmal nocturnal hemoglobinuria: clinical manifestations, haematology and nature of the disease. Ser Haematol 1972; 5: 323.